Condition
Sickling Disorder Due to Hemoglobin S
Total Trials
5
Recruiting
2
Active
2
Completed
2
Success Rate
66.7%-20% vs avg
Key Insights
Highlights
Success Rate
67% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 72/100
Termination Rate
20.0%
1 terminated out of 5 trials
Success Rate
66.7%
-19.8% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 2 completed with results
Key Signals
67% success
Data Visualizations
Phase Distribution
4Total
P 1 (1)
P 2 (3)
Trial Status
Completed2
Recruiting2
Terminated1
Trial Success Rate
66.7%
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT07015684Phase 1RecruitingPrimary
131I-apamistamab-based Conditioning for Hematopoietic Stem Cell Transplant (HSCT) in Advanced Sickle Cell Disease (SCD)
NCT04201210Phase 2Recruiting
A Trial to Assess Haploidentical T-depleted Stem Cell Transplantation in Patients With SCD
NCT02561312Completed
Comparison of Two Methods of Transfusion for Stroke Prevention in Sickle Cell
NCT01601340Phase 2Terminated
Effects of HQK-1001 in Patients With Sickle Cell Disease
NCT01322269Phase 2Completed
A Study of HQK-1001 in Patients With Sickle Cell Disease
Showing all 5 trials